All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
• Infinity Pharmaceuticals Inc., of Cambridge, Mass., expects to begin a Phase III trial of IPI-145 in chronic lymphocytic leukemia and small lymphocytic lymphoma in the fourth quarter.
